Caribou Biosciences’ (CRBU) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Caribou Biosciences (NASDAQ:CRBU) in a research note released on Wednesday,Benzinga reports. HC Wainwright currently has a $9.00 price objective on the stock. HC Wainwright also issued estimates for Caribou Biosciences’ Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS and FY2025 earnings at ($1.94) EPS.

A number of other equities analysts have also commented on CRBU. Citigroup dropped their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 26th. Bank of America dropped their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $10.33.

Caribou Biosciences Price Performance

Caribou Biosciences stock opened at $1.04 on Wednesday. Caribou Biosciences has a one year low of $0.95 and a one year high of $5.62. The company’s fifty day moving average price is $1.29 and its two-hundred day moving average price is $1.74. The company has a market capitalization of $96.73 million, a price-to-earnings ratio of -0.63 and a beta of 2.34.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The business had revenue of $2.08 million for the quarter, compared to analyst estimates of $2.11 million. As a group, sell-side analysts anticipate that Caribou Biosciences will post -1.64 earnings per share for the current year.

Institutional Investors Weigh In On Caribou Biosciences

Several hedge funds have recently modified their holdings of the business. Geode Capital Management LLC raised its stake in Caribou Biosciences by 6.5% during the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after purchasing an additional 124,782 shares during the last quarter. Barclays PLC raised its position in shares of Caribou Biosciences by 122.4% during the third quarter. Barclays PLC now owns 129,839 shares of the company’s stock valued at $255,000 after buying an additional 71,463 shares during the last quarter. US Bancorp DE raised its position in shares of Caribou Biosciences by 3,524.2% during the fourth quarter. US Bancorp DE now owns 27,218 shares of the company’s stock valued at $43,000 after buying an additional 26,467 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Caribou Biosciences by 19.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 739,530 shares of the company’s stock valued at $1,449,000 after buying an additional 118,325 shares during the period. Finally, FMR LLC grew its position in Caribou Biosciences by 7.4% during the third quarter. FMR LLC now owns 1,581,493 shares of the company’s stock worth $3,100,000 after buying an additional 109,606 shares in the last quarter. 77.51% of the stock is owned by institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.